Hints and tips:
Related Special Reports
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Pointing to increases in AstraZeneca’s research and development budget under Soriot, the successful launch of many blockbuster drugs and the expansion of the business into rare diseases, vaccines and immunology...
...“We’re looking at a place that has a relationship with industry that wants to embrace the growth,” he said of Speke, pointing to a “fantastic” existing ecosystem of biotech research and development in Liverpool...
...Melanie Ivarsson, Moderna’s chief development officer, said Britain needed to cut bureaucracy to catch up with countries like the US....
...In the past year, Novo Nordisk has become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s most valuable pharma company, on the back of high demand...
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...Spravato, a nasal spray based on a molecule from the psychedelic drug ketamine used to treat depression, already ranks as Johnson & Johnson’s fastest-growing product....
...The four pharmaceutical companies that part-funded the project — Amgen, AstraZeneca, GSK and Johnson & Johnson, — received nine months’ exclusive access to the data, which will now be made available to approved...
...Regeneron Pharmaceuticals partnered with a consortium of businesses to fund exome sequencing of biobank data....
...The business department said it was investing in science research and development capacity through the infrastructure fund and had committed to increase total UK R&D investment to 2.4 per cent of GDP — or...
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...He said Lilly had benefited from its strong research culture and breakthroughs in the two biggest untapped pharmaceutical markets....
...Johnson & Johnson is fighting a bruising battle over tens of thousands of claims its talcum powder caused cancer....
...Celebrity endorsements for a new class of weight-loss drugs are mounting up, even if they do not work on Boris Johnson, incorrigible it seems in lifestyle as in politics....
...Cancer, stroke and diabetes medications made by Merck, Johnson & Johnson and Bristol Myers Squibb are among the first tranche of medications selected for negotiation....
...Shares in Sanofi fell 19 per cent on Friday after the French pharmaceutical group announced a lower profit outlook and a spinout of its consumer care unit as it seeks to focus on drug research....
...The UK Foreign, Commonwealth and Development Office declined to comment on the case on Friday....
...Eric Topol, founder and director of the Scripps Research Translational Institute, said AI has already shown a lot of promise in reducing the time and cost of drug development, even though regulators had...
...Over the past 12 months Lilly’s shares have increased by 75 per cent, enabling the Indianapolis-based company to surpass Johnson & Johnson as the world’s most valuable drugmaker by market capitalisation....
...The US is the largest pharmaceutical market, mainly because it pays the most in the world for drugs....
...subsidiary Janssen and US drug group Merck....
...Hannah Kuchler is the FT’s global pharmaceutical editor Follow @FTMag to find out about our latest stories first...
...Stoffels spent 13 years in research and development at J&J, including helping steer the development of its Covid-19 vaccine....
...Icertis The contract management software company is working with customers, including pharmaceutical company Johnson & Johnson, drug distributor AmerisourceBergen, and Boston Consulting Group, as part of...
...Sanofi’s share price has fallen more than 4 per cent in the past year, a less drastic decline than peers Pfizer, Johnson & Johnson, and Novartis, but its shares have lagged behind peers since Hudson took...
International Edition